Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study (vol 12, 752879, 2021)

被引：0
|
作者：
Carballo, Nuria [1 ,2 ]
Garcia-Alzorriz, Enric [3 ]
Ferrandez, Olivia [1 ,2 ]
Navarrete-Rouco, Maria Eugenia [1 ]
Duran-Jorda, Xavier [4 ]
Perez-Garcia, Carolina [5 ]
Monfort, Jordi [2 ,5 ]
Cots, Francesc [3 ]
Grau, Santiago [1 ,2 ]
机构：
[1] Hosp Mar Parc Salut Mar, Pharm Dept, Barcelona, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Hosp Mar Parc Salut Mar, Management Control Dept, Barcelona, Spain
[4] Inst Hosp Mar Med Res IMIM, Methodol & Biostat Support Unit, Barcelona, Spain
[5] Hosp Mar Parc Salut Mar, Dept Rheumatol, Barcelona, Spain
来源：
FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷
关键词：
rheumatic disease; biologics; persistence; healthcare resource utilization and costs; anti TNF agents;
D O I：
10.3389/fphar.2022.867017
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：1
相关论文
共 10 条
  • [1] Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study
    Carballo, Nuria
    Garcia-Alzorriz, Enric
    Ferrandez, Olivia
    Navarrete-Rouco, Maria Eugenia
    Duran-Jorda, Xavier
    Perez-Garcia, Carolina
    Monfort, Jordi
    Cots, Francesc
    Grau, Santiago
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] THE IMPACT OF NON-PERSISTENCE ON RESOURCE UTILIZATION COSTS IN IMMUNE-MEDIATED RHEUMATIC DISEASES
    Carballo, N.
    Garcia-Alzorriz Morral, E.
    Ferrandez-Quirante, O.
    Perez-Garcia, C.
    Navarrete-Rouco, M. E.
    Duran, X.
    Monfort, J.
    Cots, F.
    Grau, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 991 - 992
  • [3] IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS
    Belhassen, M.
    Tubach, F.
    Hudry, C.
    Woronoff, M-C.
    Levy-Bachelot, L.
    Lamezec, L.
    Van Ganse, E.
    Fautrel, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 434 - 435
  • [4] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
    Johan Dalén
    Axel Svedbom
    Christopher M. Black
    Ramon Lyu
    Qian Ding
    Shiva Sajjan
    Vasilisa Sazonov
    Sumesh Kachroo
    [J]. Rheumatology International, 2016, 36 : 987 - 995
  • [5] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
    Dalen, Johan
    Svedbom, Axel
    Black, Christopher M.
    Lyu, Ramon
    Ding, Qian
    Sajjan, Shiva
    Sazonov, Vasilisa
    Kachroo, Sumesh
    [J]. RHEUMATOLOGY INTERNATIONAL, 2016, 36 (07) : 987 - 995
  • [6] SECOND LINE TREATMENT PERSISTENCE AND COSTS AMONG PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES TREATED WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Dalen, J.
    Svedbom, A.
    Black, C. M.
    Kachroo, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 447 - 447
  • [7] Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
    Svedbom, Axel
    Dalen, Johan
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 95 - 106
  • [8] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
    Dalen, Johan
    Svedbom, Axel
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. RHEUMATOLOGY INTERNATIONAL, 2017, 37 (12) : 2049 - 2058
  • [9] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
    Johan Dalén
    Axel Svedbom
    Christopher M. Black
    Sumesh Kachroo
    [J]. Rheumatology International, 2017, 37 : 2049 - 2058
  • [10] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AMONG AUSTRALIAN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASE (IMRD)
    Acar, M.
    Juneja, P.
    Agnew, J.
    Handel, M.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 24 - 24
1